https://www.selleckchem.com/products/azd9291.html
Glutamine is a critical fuel for solid tumors. Interference with glutamine metabolism is deleterious to neoplasia in preclinical models. A phase I study of the oral, first-in-class, glutaminase (GLS) inhibitor telaglenastat was conducted in treatment-refractory solid tumor patients to define recommended phase II dose (RP2D) and evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Dose escalation by 3 + 3 design was followed by exploratory tumor-/biomarker-specific cohorts. Among 120 patients, fatigue (2
Like
Comment
Share
